/NBY
NBY Stock - NovaBay Pharmaceuticals, Inc.
Healthcare|BiotechnologyAMEX
$5.30+79.66%
+$2.35 (+79.66%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NBY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.25 – $5.35
TARGET (TP)$6.09
STOP LOSS$4.88
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$6.47
52W Low$0.46
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.78M | $10.46M | $14.40M | $10.20M | $9.93M |
| Gross Profit | $6.48M | $6.08M | $7.78M | $6.51M | $5.96M |
| Gross Margin | 66.3% | 58.2% | 54.0% | 63.8% | 60.0% |
| Operating Income | $-5,839,000 | $-4,102,000 | $-14,417,000 | $-8,862,000 | $-6,426,000 |
| Net Income | $-7,223,000 | $-9,640,000 | $-10,608,000 | $-5,824,000 | $-11,039,000 |
| Net Margin | -73.8% | -92.2% | -73.6% | -57.1% | -111.1% |
| EPS | $-2.53 | $-139.14 | $-353.59 | $-184.09 | $-385.53 |
Company Overview
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NBYBeat Rate
0%
Last 19 quarters
Avg Surprise
-8463.9%
EPS vs Estimate
Beats / Misses
0/19
Last 12 quarters
Latest EPS
$-0.23
Q4 2025
EPS Surprise History
Q1 24
-10973.3%
$-33.22vs$-0.30
Q2 24
-3166.7%
$-4.90vs$-0.15
Q3 24
-11.4%
$-1.37vs$-1.23
Q4 24
-114.3%
$-0.60vs$-0.28
Q1 25
-17384.2%
$-33.22vs$-0.19
Q2 25
-154.2%
$-0.61vs$-0.24
Q3 25
-61.9%
$-0.34vs$-0.21
Q4 25
-9.5%
$-0.23vs$-0.21
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 1, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.21 | $-0.34 | -61.9% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.24 | $-0.61 | -154.2% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.19 | $-33.22 | -17384.2% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.28 | $-0.60 | -114.3% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-1.23 | $-1.37 | -11.4% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.15 | $-4.90 | -3166.7% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-0.30 | $-33.22 | -10973.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.40 | $-12.94 | -3135.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.56 | $-44.41 | -7830.4% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.91 | $-29.72 | -3165.9% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $0.17 | $-151.40 | -89158.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-1.23 | $-122.26 | -9839.8% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-1.40 | $-48.90 | -3392.9% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.05 | $-1.75 | -66.7% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-1.75 | $-24.45 | -1297.1% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-1.40 | $-61.13 | -4266.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-1.40 | $-48.90 | -3392.9% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-1.40 | $-48.90 | -3392.9% | ✗ MISS |
Latest News
Novabay Pharmaceuticals Appoints Michael Kazley As CEO And Chairman
➖ NeutralBenzinga•Oct 20, 2025, 12:50 PM
NovaBay Pharmaceuticals David Lazar Resigns As CEO
📉 NegativeBenzinga•Oct 9, 2025, 09:20 PM
NovaBay Pharmaceuticals Files For Mixed Shelf Of Up To $200M
➖ NeutralBenzinga•Oct 3, 2025, 09:28 PM
NovaBay Pharmaceuticals shares are trading higher after the company announced a one-time special cash dividend of $0.80 per share.
📈 PositiveBenzinga•Aug 27, 2025, 02:40 PM
Market-Moving News for August 27th
➖ NeutralBenzinga•Aug 27, 2025, 11:37 AM•Also: ,
NovaBay Pharmaceuticals 13D Filing Shows David E. Lazar Reported A 19.99% Stake In the Co As Of August 19, 2025
📈 PositiveBenzinga•Aug 26, 2025, 08:17 PM
NovaBay Pharmaceuticals shares are trading higher after the company announced a one-time special cash dividend of $0.80 per share.
📈 PositiveBenzinga•Aug 26, 2025, 08:14 PM
NovaBay Pharmaceuticals Announces A One-Time Special Cash Dividend Of $0.80 Per Share Payable On September 29, 2025 To Shareholders Of Record On September 15, 2025
📈 PositiveBenzinga•Aug 26, 2025, 08:09 PM
NovaBay Pharmaceuticals shares are trading higher after the company announced it entered into a $6 million securities purchase agreement with a private investor.
📈 PositiveBenzinga•Aug 20, 2025, 12:26 PM
NovaBay enters into $6M securities purchase agreement with investor David Lazar
📈 PositiveSeeking Alpha•Aug 19, 2025, 09:35 PM
NovaBay Pharmaceuticals Entered Into A $6M Securities Purchase Agreement With Private Investor David E. Lazar For The Purchase Of The Company's Non-Voting Convertible Preferred Stock; Effective Immediately, Mr.
📈 PositiveBenzinga•Aug 19, 2025, 09:31 PM
Frequently Asked Questions about NBY
What is NBY's current stock price?
NovaBay Pharmaceuticals, Inc. (NBY) is currently trading at $5.30 per share. The stock has moved +79.66% today.
What is the analyst price target for NBY?
No analyst price targets are currently available for this stock.
What sector is NovaBay Pharmaceuticals, Inc. in?
NovaBay Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is NBY's market cap?
NovaBay Pharmaceuticals, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does NBY pay dividends?
No, NovaBay Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADXN
Addex Therapeutics Ltd
$7.83
Mkt Cap: $0.0B
IBO
Impact BioMedical Inc.
$0.65
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
MTNB
Matinas BioPharma Holdings, Inc.
$0.73
Mkt Cap: $0.0B
PMCB
PharmaCyte Biotech, Inc.
$0.86
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
RADX
Radiopharm Theranostics Limited
$5.19
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VIVS
VivoSim Labs, Inc.
$1.98
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
Explore stocks similar to NBY for comparison